Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.

New expert consensus guidelines include evidence-based recommendations for cannabis use disorder treatment alongside other substance dependencies. The British Association for Psychopharmacology guidelines provide clinicians with systematic approaches to pharmacological management while acknowledging current evidence gaps in cannabis dependence treatment.

Read More

Acute toxicity of ADB-CHMINACA – a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome.

A new case series reveals that synthetic cannabinoid toxicity emergency treatment protocols are urgently needed as ADB-CHMINACA causes rapid-onset seizures and encephalopathy. Emergency physicians document severe neurologic complications occurring within minutes of synthetic cannabinoid use, highlighting critical safety differences from natural cannabis.

Read More

Cannabis Products and Contaminant Detection: Critical Review of Regulatory Oversight and Analytical Methodologies.

A comprehensive review of cannabis contaminant testing regulatory inconsistencies reveals significant gaps in safety oversight across U.S. jurisdictions. This analysis highlights critical patient safety concerns stemming from variable testing standards for heavy metals, pesticides, and other contaminants. The findings underscore the urgent need for standardized cannabis safety protocols to protect medical and adult-use consumers.

Read More